Therini Bio, Inc.

This early-stage study is testing whether a new drug called THN391 is safe for people with early Alzheimer's disease. Fifteen participants aged 65-85 will receive either the drug or a placebo injection three times over two months, followed by four months of monitoring. Researcher…